Achim A. Jungbluth - Concepedia

Author

Achim A. Jungbluth

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A A Jungbluth, A JUNGBLUTH, A Jungbluth, A. A. Jungbluth, A. Jungbluth, A.A. Jungbluth, Achim A Jungbluth, Achim A. Jungbluth, Achim A. Jungbluth., Achim Jungbluth

550

Publications

35.3K

Citations

H-Index

159

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Ludwig Cancer Research Cornell University Ludwig Cancer Research

About

Achim A. Jungbluth is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, pathology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	69	136	16.3K
2	Engineering	7	7	1K
3	Health Sciences	7	7	263
4	Natural Sciences	1	1	38
5	Public Health	1	1	109

Achim A. Jungbluth

253

Publications

31.7K

Citations

H-Index

Page 1

	Year	Citations
Intraepithelial CD8<sup>+</sup>tumor-infiltrating lymphocytes and a high CD8<sup>+</sup>/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Eiichi Sato, Sara H. Olson, Jiyoung Ahn, Proceedings of the National Academy of Sciences	2005	2.4K
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma Michael A. Postow, Margaret K. Callahan, Christopher A. Barker, New England Journal of Medicine ImmunologyPathologyDermatologyImmune SystemImmunotherapy	2012	2K
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Cancer Discovery	2018	1.5K
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1 Naomi Hunder, Herschel Wallen, Jianhong Cao, New England Journal of Medicine Cell TherapyImmunologyMelanoma-associated Antigen Ny-eso-1Refractory Metastatic MelanomaCd4 T Cell Responses	2008	894
Integrative Molecular Characterization of Malignant Pleural Mesothelioma Julija Hmeljak, Francisco Sánchez-Vega, Katherine A. Hoadley, Cancer Discovery	2018	585
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls James P. Solomon, Irina Linkov, Andrea Rosado, Modern Pathology Molecular Diagnostic TechniquesMedicineDiagnosisPathologyInnovative Diagnostics	2019	515
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma Padmanee Sharma, Yu Shen, Sijin Wen, Proceedings of the National Academy of Sciences	2007	508
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization Marina K. Baine, Min‐Shu Hsieh, W. Victoria Lai, Journal of Thoracic Oncology ImmunogeneticsSclc SubtypesHistopathologic CharacterizationAutoimmune DiseaseComprehensive Immunohistochemical	2020	468
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions Jaclyn F. Hechtman, Ryma Benayed, David M. Hyman, The American Journal of Surgical Pathology	2017	465
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans Ian D. Davis, Weisan Chen, Heather Jackson, Proceedings of the National Academy of Sciences	2004	437

Page 1